Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03521154 | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)(LAURA) | active not recruiting | Phase 3 | 216 | AstraZenecaINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 |
| clinicaltrials |
| NCT05879978 | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | active not recruiting | Phase 1 | 45 | Boehringer IngelheimINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06486428 | Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies(SUCCEED) | active not recruiting | — | 22 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06969027 | JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC | active not recruiting | Phase 2 | 69 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02496663 | Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | active not recruiting | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02888743 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT02905591 | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC(XACT-LUNG) | active not recruiting | Phase 2 | 43 | Joseph J. Cullen, MD, FACSOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03300817 | MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03896503 | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | active not recruiting | Phase 2 | 104 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04093167 | Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 53 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT05715255 | Adaptive Symptom Self-Management Immunotherapy Study | active not recruiting | N/A | 400 | University of ArizonaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04606771 | A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC(CoC) | active not recruiting | Phase 2 | 30 | AstraZenecaINDUSTRY | 6 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT02178163 | Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer | active not recruiting | N/A | 619 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03425643 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | active not recruiting | Phase 3 | 797 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 29, 2026 | clinicaltrials |
| NCT05247684 | AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | active not recruiting | Phase 2 | 90 | AkesoINDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03141359 | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | active not recruiting | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05599789 | Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)(KeyPemls-004) | active not recruiting | Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05844761 | Real-time Motion Management During Prostate and Lung Radiotherapy(REMIND) | active not recruiting | N/A | 132 | Region SkaneOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | active not recruiting | Phase 2 | 66 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05984277 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.(eVOLVE-Lung02) | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 25 | Jul 28, 2026 | clinicaltrials |
| NCT06396065 | Phase III Study of AK112 for NSCLC Patients | active not recruiting | Phase 3 | 420 | Summit TherapeuticsINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT06644768 | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | active not recruiting | Phase 1 / Phase 2 | 137 | Daiichi SankyoINDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT04612751 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung04) | active not recruiting | Phase 1 | 155 | AstraZenecaINDUSTRY | 8 | Jul 27, 2026 | clinicaltrials |
| NCT06944470 | JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC | active not recruiting | Phase 2 | 78 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06992609 | Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.(ALBORAN) | active not recruiting | Phase 3 | 68 | AstraZenecaINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT01696968 | Screening for Lung Cancer in Older Patients (PLCO Screening Trial) | active not recruiting | N/A | 154,901 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03693014 | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | active not recruiting | Phase 2 | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04258137 | Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study(COPE) | active not recruiting | N/A | 332 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 762 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 23, 2026 | clinicaltrials |
| NCT06382116 | A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) | active not recruiting | Phase 3 | 432 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | active not recruiting | Phase 1 / Phase 2 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors(innovaTV 207) | active not recruiting | Phase 2 | 350 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT04166487 | Plasma-Adapted First-Line Pembro In NSCLC | active not recruiting | Phase 2 | 40 | Julia K. Rotow, MDOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | active not recruiting | Phase 1 / Phase 2 | 200 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT01933932 | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC(SELECT-1) | active not recruiting | Phase 3 | 510 | AstraZenecaINDUSTRY | 26 | Jul 21, 2026 | clinicaltrials |
| NCT06472076 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 88 | GlaxoSmithKlineINDUSTRY | 21 | Jul 21, 2026 | clinicaltrials |
| NCT06698042 | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | active not recruiting | Phase 3 | 67 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Jul 21, 2026 | clinicaltrials |
| NCT07712016 | Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease(TAME-CLC) | active not recruiting | — | 27,000 | Seoul National UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07718139 | Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada | active not recruiting | — | 300 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02143466 | AZD9291 in Combination With Ascending Doses of Novel Therapeutics | active not recruiting | Phase 1 | 344 | AstraZenecaINDUSTRY | 8 | Jul 20, 2026 | clinicaltrials |
| NCT03833154 | Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation(PACIFIC-4) | active not recruiting | Phase 3 | 724 | AstraZenecaINDUSTRY | 20 | Jul 20, 2026 | clinicaltrials |
| NCT06607185 | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | active not recruiting | Phase 1 | 750 | Eli Lilly and CompanyINDUSTRY | 8 | Jul 20, 2026 | clinicaltrials |
| NCT04285671 | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05334329 | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | active not recruiting | Phase 1 | 6 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2026source: clinicaltrials